Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

83 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Subcutaneous Ustekinumab Provides Clinical Benefit for Two-Thirds of Patients With Crohn's Disease Refractory to Anti-Tumor Necrosis Factor Agents.
Wils P, Bouhnik Y, Michetti P, Flourie B, Brixi H, Bourrier A, Allez M, Duclos B, Grimaud JC, Buisson A, Amiot A, Fumery M, Roblin X, Peyrin-Biroulet L, Filippi J, Bouguen G, Abitbol V, Coffin B, Simon M, Laharie D, Pariente B; Groupe d'Etude Thérapeutique des Affections Inflammatoires du Tube Digestif. Wils P, et al. Clin Gastroenterol Hepatol. 2016 Feb;14(2):242-50.e1-2. doi: 10.1016/j.cgh.2015.09.018. Epub 2015 Sep 30. Clin Gastroenterol Hepatol. 2016. PMID: 26432476 Free article.
Reply.
Pariente B, Wils P, Laharie D. Pariente B, et al. Among authors: wils p. Gastroenterology. 2016 May;150(5):1239. doi: 10.1053/j.gastro.2016.03.022. Epub 2016 Mar 25. Gastroenterology. 2016. PMID: 27020336 No abstract available.
Ileal or Anastomotic Location of Lesions Does Not Impact Rate of Postoperative Recurrence in Crohn's Disease Patients Classified i2 on the Rutgeerts Score.
Bayart P, Duveau N, Nachury M, Zerbib P, Gerard R, Branche J, Maunoury V, Wils P, Boruchowicz A, Boualit M, Laberenne JE, Manolache O, Desreumaux P, de Chambrun GP, Pariente B. Bayart P, et al. Among authors: wils p. Dig Dis Sci. 2016 Oct;61(10):2986-2992. doi: 10.1007/s10620-016-4215-1. Epub 2016 Jul 11. Dig Dis Sci. 2016. PMID: 27401274
Efficacy and safety of golimumab in Crohn's disease: a French national retrospective study.
Martineau C, Flourié B, Wils P, Vaysse T, Altwegg R, Buisson A, Amiot A, Pineton de Chambrun G, Abitbol V, Fumery M, Hébuterne X, Viennot S, Laharie D, Beaugerie L, Nancey S, Sokol H; Goli-Crohn Study Group. Martineau C, et al. Among authors: wils p. Aliment Pharmacol Ther. 2017 Dec;46(11-12):1077-1084. doi: 10.1111/apt.14371. Epub 2017 Oct 13. Aliment Pharmacol Ther. 2017. PMID: 29027693
Long-term efficacy and safety of ustekinumab in 122 refractory Crohn's disease patients: a multicentre experience.
Wils P, Bouhnik Y, Michetti P, Flourie B, Brixi H, Bourrier A, Allez M, Duclos B, Serrero M, Buisson A, Amiot A, Fumery M, Roblin X, Peyrin-Biroulet L, Filippi J, Bouguen G, Abitbol V, Coffin B, Simon M, Laharie D, Pariente B; Groupe d'Etude Thérapeutique des Affections Inflammatoires du Tube Digestif (GETAID). Wils P, et al. Aliment Pharmacol Ther. 2018 Mar;47(5):588-595. doi: 10.1111/apt.14487. Epub 2018 Jan 8. Aliment Pharmacol Ther. 2018. PMID: 29315694
83 results